Stock Performance Overview
On 27 March 2026, Mukka Proteins Ltd closed at Rs.20, setting a new 52-week and all-time low. The stock recorded a day decline of 2.00%, slightly underperforming the Sensex’s 1.60% fall on the same day. Over the past week, the stock has lost 4.51%, compared to a modest 0.62% decline in the Sensex. The one-month performance shows a sharper drop of 11.45%, exceeding the Sensex’s 8.88% fall. The three-month and year-to-date returns stand at -16.70% and -16.28% respectively, both lagging behind the Sensex’s corresponding declines of -12.90% and -13.08%.
Most notably, the stock has delivered a negative 38.72% return over the last year, a stark contrast to the Sensex’s modest 4.55% decline. Over longer horizons, Mukka Proteins has failed to generate any positive returns over three, five, and ten years, while the Sensex has appreciated by 28.48%, 51.14%, and 192.34% respectively during these periods.
Technical Indicators and Market Context
The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish trend. The overall technical trend is classified as bearish since 24 March 2026, with key resistance levels identified at Rs.21.79 (20-day moving average), Rs.23.65 (100-day moving average), and Rs.25.87 (200-day moving average). Immediate support is at Rs.20.20, the 52-week low.
Market activity shows increased delivery volumes, with a 27.06% rise in one-day delivery compared to the five-day average, and a 24.5% increase over the past month. Despite this, the stock’s relative performance remains weak, even as the broader aquaculture sector has declined by 3.52%.
Financial and Quality Assessment
Mukka Proteins Ltd’s financial metrics reveal underlying challenges. The company’s long-term growth has been negative, with a compound annual growth rate (CAGR) of -4.98% in operating profits over the past five years. Its ability to service debt is constrained, evidenced by a high Debt to EBITDA ratio of 5.26 times. Return on Capital Employed (ROCE) averages 9.16%, indicating limited profitability relative to the capital invested.
The company’s quality grade is below average, reflecting weaknesses in management risk, growth, and capital structure. Key indicators include a 5-year sales decline of -3.07%, an average EBIT to interest coverage ratio of 2.87x, and a net debt to equity ratio of 1.25, signalling elevated leverage. Institutional investor participation is low, with holdings at 1.86%, down by 1.5% from the previous quarter.
Recent Quarterly Financial Highlights
Despite the broader downtrend, Mukka Proteins reported positive quarterly results in December 2025 after seven consecutive quarters of negative performance. The company posted a PAT of Rs.23.75 crores, growing 101.1% compared to the previous four-quarter average. Net sales reached a quarterly high of Rs.653.50 crores, while PBDIT also peaked at Rs.45.44 crores. However, interest expenses were elevated at Rs.14.56 crores for the quarter.
These results, while encouraging in isolation, have not translated into a sustained improvement in the stock’s market performance or valuation metrics.
Valuation Metrics
At the current price of Rs.20.10, Mukka Proteins trades at a price-to-earnings (P/E) ratio of 14x and a price-to-book value (P/BV) of 1.38x. The enterprise value to EBITDA ratio stands at 10.66x, with an EV to capital employed ratio of 1.17x. These multiples suggest the stock is valued at a discount relative to its historical peer averages.
Dividend metrics are not applicable, as the company has not declared dividends recently. The stock’s valuation parameters have declined in line with its financial performance and market sentiment.
Sector and Market Comparison
Mukka Proteins operates within the FMCG sector, specifically in the aquaculture segment, which has itself experienced a decline of 3.52% recently. The company’s underperformance relative to both the sector and the broader market highlights the severity of its current position. While the Sensex has shown resilience, Mukka Proteins’ stock has consistently lagged, reflecting structural and financial headwinds.
Summary of Key Challenges
The stock’s fall to an all-time low is underpinned by a combination of weak long-term financial growth, high leverage, and below-average profitability. The company’s limited ability to generate returns on capital and service debt has weighed on investor confidence, as reflected in the low institutional ownership and persistent share price declines. Despite a brief positive quarterly earnings report, the overall trend remains subdued, with valuation multiples reflecting the cautious market stance.
Conclusion
Mukka Proteins Ltd’s stock reaching a new all-time low on 27 March 2026 underscores the challenges faced by the company in maintaining financial and market momentum. The stock’s performance across multiple timeframes, combined with technical and fundamental indicators, paints a picture of sustained pressure. While recent quarterly results showed some improvement, the broader financial and market context continues to reflect a difficult environment for the company.
